Clinical failure of the amalgam restoration usually occurs from:
a- Improper cavity preparation***
b- Faulty manipulation.
c- Both of the above
d- None of the above.
The Toulouse biotech, specializing in cardiovascular diseases, announced the failure of the CARAT clinical trial. Investors have erased from their model the value of this project, on which all hopes rested.
After 48 hours of listing suspension, the long-awaited press release was published last night: the CARAT study is a failure. Cerenis cashed this morning, an inevitable tsunami stock market. The title of the Toulouse biotech shrank by 82% at mid-session.
This intermediate-phase clinical trial (IIb) assessed the ability of CER-001 - the drug candidate of Cerenis - to reduce the risk of recurrence in patients with prior acute coronary syndrome (ACS) following myocardial infarction. or angina pectoris. Its mechanism of action: reduce the volume of atherosclerotic plaque (or atherosclerosis) in the blood vessels.
The statement is pithy: "No statistical difference observed between the treatment and the placebo" was observed on the main criterion, in this case the volume of atheroma, observed by echography of the coronary arteries. CEO Jean-Louis Dasseux said he was "surprised and disappointed".
Balls in the Nash:
This program is not the most advanced at Cerenis. The company is currently conducting a final clinical trial called TANGO, with the same molecule, in a rare disease, Familial Hypoalphaliporoteinemia (FPHA). The results should be released in the third quarter. Cerenis has other molecules including CER-009 that could be the subject of a first study in humans (phase I clinical trial) this year in non-alcoholic fatty liver disease (NASH).
But the profile of CER-001 in the post-SCA indication had fueled the hopes of investors. This product promises to be the first to significantly reduce bad cholesterol (LDL) and not just to slow down the formation of plaque (as do statins).
A therapeutic revolution in power and a gigantic commercial potential, since the market for medicines intended to reduce cholesterol is close to 20 billion dollars.
60 to 90% of the valuation of the company
The analysts who cover Cerenis attributed to this program between 60 and 90% of the stock market value of the company. Hence the magnitude of the fall. Before going public, the company - which has raised more than 170 million euros since its creation ten years ago - had already failed in 2012, in the same indication, with a different dosage. This second failure is hard to swallow for investors.
Of course, not everything is lost. The company will further analyze CARAT's clinical data to try to identify respondent subgroups among the 301 patients in the study. Rendez-vous March 17, for the detailed presentation of the results at the conference of the American College of Cardiology. In the meantime, investor mistrust will remain (very) strong on this issue.
a- Improper cavity preparation***
b- Faulty manipulation.
c- Both of the above
d- None of the above.
The Toulouse biotech, specializing in cardiovascular diseases, announced the failure of the CARAT clinical trial. Investors have erased from their model the value of this project, on which all hopes rested.
After 48 hours of listing suspension, the long-awaited press release was published last night: the CARAT study is a failure. Cerenis cashed this morning, an inevitable tsunami stock market. The title of the Toulouse biotech shrank by 82% at mid-session.
This intermediate-phase clinical trial (IIb) assessed the ability of CER-001 - the drug candidate of Cerenis - to reduce the risk of recurrence in patients with prior acute coronary syndrome (ACS) following myocardial infarction. or angina pectoris. Its mechanism of action: reduce the volume of atherosclerotic plaque (or atherosclerosis) in the blood vessels.
The statement is pithy: "No statistical difference observed between the treatment and the placebo" was observed on the main criterion, in this case the volume of atheroma, observed by echography of the coronary arteries. CEO Jean-Louis Dasseux said he was "surprised and disappointed".
Balls in the Nash:
This program is not the most advanced at Cerenis. The company is currently conducting a final clinical trial called TANGO, with the same molecule, in a rare disease, Familial Hypoalphaliporoteinemia (FPHA). The results should be released in the third quarter. Cerenis has other molecules including CER-009 that could be the subject of a first study in humans (phase I clinical trial) this year in non-alcoholic fatty liver disease (NASH).
But the profile of CER-001 in the post-SCA indication had fueled the hopes of investors. This product promises to be the first to significantly reduce bad cholesterol (LDL) and not just to slow down the formation of plaque (as do statins).
A therapeutic revolution in power and a gigantic commercial potential, since the market for medicines intended to reduce cholesterol is close to 20 billion dollars.
60 to 90% of the valuation of the company
The analysts who cover Cerenis attributed to this program between 60 and 90% of the stock market value of the company. Hence the magnitude of the fall. Before going public, the company - which has raised more than 170 million euros since its creation ten years ago - had already failed in 2012, in the same indication, with a different dosage. This second failure is hard to swallow for investors.
Of course, not everything is lost. The company will further analyze CARAT's clinical data to try to identify respondent subgroups among the 301 patients in the study. Rendez-vous March 17, for the detailed presentation of the results at the conference of the American College of Cardiology. In the meantime, investor mistrust will remain (very) strong on this issue.
Labels
Community dentistry